Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy

Yolanda Barrón, Stephen R. Cole, Ruth M. Greenblatt, Mardge H. Cohen, Kathryn Anastos, Jack A. DeHovitz, Robert Delapenha, Stephen J. Gange

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Objective: To estimate the effect of discontinuing antiretroviral therapy (ART) on survival, among women who initiated highly active antiretroviral therapy (HAART). Design: A multicenter cohort study. Methods: A total of 951 HAART-initiated women were followed for total mortality between 1995 and 2002. The relative hazard (RH) of death attributable to discontinuing all ART was estimated using an inverse probability of treatment-weighted marginal structural Cox proportional hazards model, as well as standard Cox models. Results: Three hundred and forty-three out of 951 women discontinued all ART during the 3187 person-years of follow-up, and 116 died. The RH of death attributable to discontinuation was 1.97 [95% confidence interval (CI) 1.17, 3.31] from the marginal structural Cox model. A RH of 1.49 (95% CI 0.94, 2.35) was observed using the same set of covariates in a standard Cox model. Conclusion: An increased risk of mortality for those HAART initiators who discontinued ART was observed using a marginal structural Cox model. This increased risk was independent of measured treatment failure, and was greatly attenuated in a standard Cox model with time-varying covariates.

Original languageEnglish (US)
Pages (from-to)1579-1584
Number of pages6
JournalAIDS
Volume18
Issue number11
DOIs
StatePublished - Jul 23 2004
Externally publishedYes

Keywords

  • Antiretroviral therapy
  • Cohort studies
  • Confounding
  • Discontinuation
  • HIV/AIDS

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy'. Together they form a unique fingerprint.

Cite this